Back to Search Start Over

Transcriptome-wide analysis reveals insight into tumor suppressor functions of 1B3, a novel synthetic miR-193a-3p mimic.

Authors :
van den Bosch MTJ
Yahyanejad S
Alemdehy MF
Telford BJ
de Gunst T
den Boer HC
Vos RM
Stegink M
van Pinxteren LAH
Schaapveld RQJ
Janicot M
Source :
Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2021 Jan 26; Vol. 23, pp. 1161-1171. Date of Electronic Publication: 2021 Jan 26 (Print Publication: 2021).
Publication Year :
2021

Abstract

Emerging data show that microRNA 193a-3p (miR-193a-3p) has a suppressive role in many cancers and is often downregulated in tumors, as compared to surrounding normal tissues. Therefore, mimics of miR-193a-3p could be used as an attractive therapeutic approach in oncology. To better understand and document the molecular mechanism of action of 1B3, a novel synthetic miRNA-193a-3p mimic, RNA sequencing was performed after transfection of 1B3 in six different human tumor cell lines. Genes differentially expressed (DE) in at least three cell lines were mapped by Ingenuity Pathway Analysis (IPA), and interestingly, these results strongly indicated upregulation of the tumor-suppressive phosphatase and tensin homolog (PTEN) pathway, as well as downregulation of many oncogenic growth factor signaling pathways. Importantly, although unsurprisingly, IPA identified miR-193a-3p as a strong upstream regulator of DE genes in an unbiased manner. Furthermore, biological function analysis pointed to an extensive link of 1B3 with cancer, via expected effects on tumor cell survival, proliferation, migration, and cell death. Our data strongly suggest that miR-193a-3p/1B3 is a potent tumor suppressor agent that targets various key oncogenic pathways across cancer types. Therefore, the introduction of 1B3 into tumor cells may represent a promising strategy for cancer treatment.<br />Competing Interests: All authors are employees of InteRNA Technologies BV and hold stock options in the company. R.Q.J.S., L.A.H.v.P., and M.J. are also minority shareholders (<5%) in InteRNA Technologies BV.<br /> (© 2021 The Author(s).)

Details

Language :
English
ISSN :
2162-2531
Volume :
23
Database :
MEDLINE
Journal :
Molecular therapy. Nucleic acids
Publication Type :
Academic Journal
Accession number :
33664995
Full Text :
https://doi.org/10.1016/j.omtn.2021.01.020